Suppression of the expression or activities of enzymes that are involved in the synthesis of
de novo
lipogenesis (
DNL
) in cancer cells triggers cell death via apoptosis. The plasma membrane citrate transporter (
PMCT
) is the initial step that translocates citrate from blood circulation into the cytoplasm for
de novo
long‐chain fatty acids synthesis. This study investigated the antitumor effect of the
PMCT
inhibitor (
PMCT
i) in inducing apoptosis by inhibiting the
DNL
pathway in HepG2 cells. The present findings showed that
PMCT
i reduced cell viability and enhanced apoptosis through decreased intracellular citrate levels, which consequently caused inhibition of fatty acid and triacylglycerol productions. Thus, as a result of the reduction in fatty acid synthesis, the activity of carnitine palmitoyl transferase‐1 (
CPT
‐1) was suppressed. Decreased
CPT
‐1 activity also facilitated the disruption of mitochondrial membrane potential (ΔΨm) leading to stimulation of apoptosis. Surprisingly, primary human hepatocytes were not affected by
PMCT
i. Increased caspase‐8 activity as a consequence of reduction in fatty acid synthesis was also found to cause disruption of ΔΨm. In addition, apoptosis induction by
PMCT
i was associated with an enhanced reactive oxygen species generation. Taken together, we suggest that inhibition of the
DNL
pathway following reduction in citrate levels is an important regulator of apoptosis in HepG2 cells via suppression of
CPT
‐1 activity. Thus, targeting the
DNL
pathway mediating
CPT
‐1 activity by
PMCT
i may be a selective potential anticancer therapy.